相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1910
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- GLP-1 agonists may reduce pulmonary fibrosis in people with type 2 diabetes suffering from Long COVID, according to new mouse model research published in the Journal of Virology. - People with diabetes face a risk of severe Long COVID symptoms that is four times higher than those without diabetes, though the underlying mechanisms remain poorly understood. - Treated mice showed normalized fibrosis-related genes and reduced lung scarring compared to untreated mice, suggesting GLP-1 agonists can "reprogram" macrophages responsible for scar tissue buildup. - Researchers caution the findings are preliminary proof-of-concept involving a small number of mice, but express optimism that the treatment warrants further investigation.
- The University of Hong Kong and Grand Pharmaceutical Group Limited have signed a research collaboration agreement to advance innovative drug development through industry-academia integration. - The first collaborative project focuses on developing novel therapeutic solutions with high efficacy and safety profiles to address urgent unmet clinical needs in anti-infective treatments. - Upon successful completion, Grand Pharmaceutical will take exclusive licensing rights to the resulting intellectual property and handle subsequent development, regulatory approval, and commercialization. - The partnership combines HKU's expertise in medicinal chemistry with Grand Pharmaceutical's clinical development and commercialization capabilities to accelerate translation of research into patient treatments.
- Researchers at the University of Hong Kong discovered that finerenone, a diabetes medication, can restore follicular development in women with premature ovarian insufficiency. - A 2024 clinical trial involving 14 patients showed that slightly over half of participants experienced improved follicular development after taking finerenone twice weekly for up to seven months. - The breakthrough offers new hope for women under 40 with POI, a condition affecting up to 3% of women globally and for which conventional IVF treatment is ineffective. - The drug demonstrated minimal side effects and remains affordable at approximately HK$200, with researchers planning expanded trials across multiple hospitals.
- A comprehensive meta-analysis of over 80,000 patients with diabetes and heart disease found no significant association between GLP-1 receptor agonist use and ischaemic optic neuropathy risk. - The study represents the largest sample size examined to date for evaluating vision-threatening complications associated with this emerging cardiometabolic drug class. - Additional research demonstrated that every 1% weight reduction in obese atrial fibrillation patients was associated with a 6.3% reduction in relative risk of AF recurrence after catheter ablation. - The findings provide clearer evidence for clinicians to perform comprehensive risk-benefit assessments when prescribing GLP-1 receptor agonists for cardiovascular patients.
- The Hong Kong government officially established the Real-World Study and Application Centre under the Greater Bay Area International Clinical Trial Institute to leverage medical data for drug registration and market entry. - The center will integrate real-world data from Hong Kong-registered drugs and medical devices used in mainland healthcare institutions, with 140 products already benefiting over 17,000 patient visits. - A collaboration with the University of Hong Kong and GSK marks the first real-world data research project, with data collection expected to begin in the second quarter of next year. - The simultaneous launch of the GBA Clinical Trial Collaboration Platform creates a unified service portal to match global biomedical enterprises with suitable research institutions across the region.
- A randomized clinical trial of 135 participants published in the European Heart Journal found that intensive periodontitis treatment significantly slowed carotid artery thickening compared to standard dental cleaning over two years. - The study demonstrated that intensive gum disease treatment reduced inflammatory and oxidative stress markers while improving blood vessel function, targeting cardiovascular risk through inflammation rather than traditional cholesterol pathways. - Results showed arterial benefits comparable to lifestyle interventions and pharmacological agents, reinforcing periodontitis as a modifiable risk factor for vascular aging and cardiovascular events. - Study limitations include single-location conduct and inclusion of only otherwise healthy participants, meaning results may not apply to patients with existing atherosclerosis.
- Precision BioSciences' PBGENE-HBV demonstrated substantial antiviral activity in all three patients in the lowest dose cohort, achieving 47-69% reductions in hepatitis B surface antigen levels. - The gene editing therapy showed a well-tolerated safety profile with no serious adverse events or dose-limiting toxicities observed across multiple dose administrations. - One patient maintained a durable 50% reduction in HBsAg levels seven months after initial treatment, providing first clinical evidence of sustained viral DNA editing. - PBGENE-HBV represents the first and only clinical modality designed to eliminate covalently closed circular DNA and inactivate integrated DNA for potential hepatitis B cure.
- Ropeginterferon alfa-2b achieved a 42.9% sustained response rate compared to 6.0% with anagrelide in patients with essential thrombocythemia resistant or intolerant to hydroxyurea. - The drug demonstrated superior molecular responses with 27.8% partial and 2.8% complete molecular responses, while anagrelide showed no molecular responses. - Ropeginterferon alfa-2b significantly reduced thrombotic events to 1.1% versus 8.8% with anagrelide and showed better safety profile with fewer treatment discontinuations. - The SURPASS-ET trial results support ropeginterferon as a promising disease-modifying therapy for high-risk essential thrombocythemia patients.
- The 2025 European Hematology Association Congress featured promising clinical trial results across multiple hematologic cancers, with novel trispecific and bispecific antibodies showing exceptional response rates in challenging patient populations. - JNJ-5332, a trispecific antibody targeting CD3, BCMA, and GPRC5D, achieved 70.4% complete response rates in BCMA/GPRC5D-naïve multiple myeloma patients, comparable to CAR-T therapy but as an off-the-shelf outpatient treatment. - The combination of talquetamab and teclistamab demonstrated a 78.9% overall response rate in multiple myeloma patients with extramedullary disease, a historically difficult-to-treat population with poor outcomes. - POLARGO trial results showed polatuzumab vedotin-based therapy reduced death risk by 40% in relapsed/refractory diffuse large B-cell lymphoma, offering new treatment options for transplant-ineligible patients.
- Scientists at the University of Hong Kong's Li Ka Shing Faculty of Medicine have developed a novel needle-free nasal flu vaccine that shows potential for broader protection against multiple influenza strains. - Preclinical studies in mice demonstrated superior protection compared to existing live-attenuated and inactivated vaccines, with robust immune responses against both human and avian influenza viruses. - The innovative approach may eliminate the need for annual vaccinations, though researchers will conduct further clinical studies to determine antibody persistence and optimal dosing frequency.
